[go: up one dir, main page]

WO2011084618A3 - Compositions et procédés d'administration de médicaments par voie orale - Google Patents

Compositions et procédés d'administration de médicaments par voie orale Download PDF

Info

Publication number
WO2011084618A3
WO2011084618A3 PCT/US2010/060809 US2010060809W WO2011084618A3 WO 2011084618 A3 WO2011084618 A3 WO 2011084618A3 US 2010060809 W US2010060809 W US 2010060809W WO 2011084618 A3 WO2011084618 A3 WO 2011084618A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
drug delivery
oral drug
compositions
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/060809
Other languages
English (en)
Other versions
WO2011084618A2 (fr
Inventor
William W. Lee
Feng Lu
Yin Min
Liuying Shao
Hao SHE
Zhou Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOD Pharmaceuticals Inc
Original Assignee
NOD Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN200910201248.3A external-priority patent/CN102100912B/zh
Priority claimed from CN201010227045.4A external-priority patent/CN102335431B/zh
Application filed by NOD Pharmaceuticals Inc filed Critical NOD Pharmaceuticals Inc
Priority to JP2012544835A priority Critical patent/JP2013514976A/ja
Priority to CA2784120A priority patent/CA2784120A1/fr
Priority to EP10795591A priority patent/EP2512454A2/fr
Priority to AU2010339907A priority patent/AU2010339907A1/en
Publication of WO2011084618A2 publication Critical patent/WO2011084618A2/fr
Publication of WO2011084618A3 publication Critical patent/WO2011084618A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une composition pharmaceutique pour l'administration de médicaments par voie orale comprenant une forme pharmaceutique solide contenant une quantité efficace d'un agent thérapeutique, un promoteur de perméation et un excipient pharmaceutiquement acceptable et une couche bioadhésive contenant un polymère bioadhésif, et comprenant, éventuellement, une couche imperméable ou semi-perméable comportant une ouverture capable d'orienter la libération unidirectionnelle de l'agent thérapeutique et du promoteur de perméation à partir de la forme pharmaceutique solide. Des procédés de préparation et d'utilisation de la présente composition pharmaceutique sont également décrits.
PCT/US2010/060809 2009-12-16 2010-12-16 Compositions et procédés d'administration de médicaments par voie orale Ceased WO2011084618A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012544835A JP2013514976A (ja) 2009-12-16 2010-12-16 経口薬物送達のための組成物および方法
CA2784120A CA2784120A1 (fr) 2009-12-16 2010-12-16 Compositions et procedes d'administration de medicaments par voie orale
EP10795591A EP2512454A2 (fr) 2009-12-16 2010-12-16 Compositions et procedes d'administration de medicaments par voie orale
AU2010339907A AU2010339907A1 (en) 2009-12-16 2010-12-16 Compositions and methods for oral drug delivery

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US28714609P 2009-12-16 2009-12-16
CN200910201248.3 2009-12-16
CN200910201248.3A CN102100912B (zh) 2009-12-16 2009-12-16 一种给药组合物及其制备和使用方法
US61/287,146 2009-12-16
CN201010227045.4A CN102335431B (zh) 2010-07-14 2010-07-14 一种给药组合物及其制备和使用方法
CN201010227045.4 2010-07-14
US36591610P 2010-07-20 2010-07-20
US61/365,916 2010-07-20

Publications (2)

Publication Number Publication Date
WO2011084618A2 WO2011084618A2 (fr) 2011-07-14
WO2011084618A3 true WO2011084618A3 (fr) 2012-01-19

Family

ID=44306059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/060809 Ceased WO2011084618A2 (fr) 2009-12-16 2010-12-16 Compositions et procédés d'administration de médicaments par voie orale

Country Status (5)

Country Link
EP (1) EP2512454A2 (fr)
JP (1) JP2013514976A (fr)
AU (1) AU2010339907A1 (fr)
CA (1) CA2784120A1 (fr)
WO (1) WO2011084618A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103557B2 (en) 2014-03-21 2021-08-31 Anygen Co., Ltd. Exenatide analogue and use thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (fr) 2011-04-12 2012-10-18 Novo Nordisk A/S Derives de glp-1 a double acylation
CA2838793C (fr) * 2011-07-19 2019-08-06 Baxter International Inc. Activateurs de resorption comme additifs pour ameliorer la formulation orale de polysaccharides sulfates non anticoagulants
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
WO2015010927A1 (fr) * 2013-07-24 2015-01-29 Novo Nordisk A/S Composition pharmaceutique pour administration orale d'insuline comprenant un cœur de comprimé et un enrobage de copolymère anionique
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3142645A4 (fr) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Compositions pharmaceutiques et procédés de fabrication de masses solides comprenant des polypeptides et/ou des protéines
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN107205949A (zh) * 2015-01-29 2017-09-26 诺和诺德股份有限公司 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
EP3250225A1 (fr) * 2015-01-29 2017-12-06 Novo Nordisk A/S Composition pharmaceutique pour l'administration d'insuline par voie orale comprenant un noyau de comprimé et un enrobage d'alcool polyvinylique
UA123051C2 (uk) * 2015-04-08 2021-02-10 Торрент Фармасьютікалз Лімітед Фармацевтичні склади
CN113546036A (zh) 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
CN104998251A (zh) * 2015-07-08 2015-10-28 哈尔滨吉象隆生物技术有限公司 用于口服肠溶制剂制备的具有促肠吸收作用的利拉鲁肽盐
CN105079794A (zh) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 一种可用于口服的利拉鲁肽与磺脲类复方制剂
CN105079793A (zh) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 一种可用于口服的利拉鲁肽与盐酸二甲双胍复方制剂
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP4122483B1 (fr) * 2020-03-18 2025-04-30 Xizang Haisco Pharmaceutical Co., Ltd. Composition pharmaceutique orale
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454383A1 (fr) * 1990-04-23 1991-10-30 Aicello Chemical Co., Ltd. Formulation orale contenant des polypeptides dissociables dans le gros intestin
EP0460921A2 (fr) * 1990-06-04 1991-12-11 Aicello Chemical Company Limited Capsules dures désintégrables dans le gros intestin
WO1998032426A1 (fr) * 1997-01-29 1998-07-30 Polin Industria Chimica S.P.A. Formes posologiques a liberation lente a partir d'un moment precis et techniques de preparation
WO2000041740A2 (fr) * 1999-01-11 2000-07-20 The Regents Of The University Of California Particules servant a l'administration orale de peptides et de proteines
US20020044975A1 (en) * 1994-04-22 2002-04-18 Shunsuke Watanabe Colon-specific drug release system
WO2005002549A1 (fr) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Compositions pharmaceutiques contenant une hormone parathyroide (pth) administrees par voie orale

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
EP0200508B1 (fr) 1985-04-27 1991-10-02 Nitto Denko Corporation Emplâtres adhésifs et préparations pharmaceutiques pour la cavité buccale
HU198626B (en) 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
US6156731A (en) 1989-05-10 2000-12-05 G. D. Searle & Co. Polypeptide composition for oral administration
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
CA2070061C (fr) 1991-06-07 2004-02-10 Shigeyuki Takama Composition pharmaceutique renfermant des polypeptides physiologiquement actives
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5424289A (en) 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
ATE220911T1 (de) 1994-11-17 2002-08-15 Toray Industries Transdermal absorbierbare zubereitung
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5817624A (en) 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
CA2184316A1 (fr) 1995-09-12 1997-03-13 Wei-Chi Liao Systeme d'administration buccale pour agents therapeutiques
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU717183B2 (en) 1996-10-30 2000-03-16 Theratech, Inc. Fatty acid esters of lactic acid salts as permeation enhancers
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
JPH11246439A (ja) 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
CA2352389C (fr) 1998-11-27 2009-01-20 Kanji Takada Preparation orale servant a diffuser un medicament du tube digestif
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
ATE470433T1 (de) 2004-02-13 2010-06-15 Nod Pharmaceuticals Inc Partikel mit kern aus calciumphosphat- nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
WO2006014673A2 (fr) 2004-07-19 2006-02-09 Nobex Corporation Conjugues insuline-oligomere, preparations et utilisations de ceux-ci
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090087484A1 (en) 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20090111736A1 (en) 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
EP2285361A2 (fr) 2008-05-01 2011-02-23 Nod Pharmaceuticals, Inc. Particules de phosphate de calcium thérapeutiques et procédés pour les fabriquer et les utiliser

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454383A1 (fr) * 1990-04-23 1991-10-30 Aicello Chemical Co., Ltd. Formulation orale contenant des polypeptides dissociables dans le gros intestin
EP0460921A2 (fr) * 1990-06-04 1991-12-11 Aicello Chemical Company Limited Capsules dures désintégrables dans le gros intestin
US20020044975A1 (en) * 1994-04-22 2002-04-18 Shunsuke Watanabe Colon-specific drug release system
WO1998032426A1 (fr) * 1997-01-29 1998-07-30 Polin Industria Chimica S.P.A. Formes posologiques a liberation lente a partir d'un moment precis et techniques de preparation
WO2000041740A2 (fr) * 1999-01-11 2000-07-20 The Regents Of The University Of California Particules servant a l'administration orale de peptides et de proteines
WO2005002549A1 (fr) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Compositions pharmaceutiques contenant une hormone parathyroide (pth) administrees par voie orale

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103557B2 (en) 2014-03-21 2021-08-31 Anygen Co., Ltd. Exenatide analogue and use thereof

Also Published As

Publication number Publication date
WO2011084618A2 (fr) 2011-07-14
EP2512454A2 (fr) 2012-10-24
AU2010339907A1 (en) 2012-07-05
JP2013514976A (ja) 2013-05-02
CA2784120A1 (fr) 2011-07-14

Similar Documents

Publication Publication Date Title
WO2011084618A3 (fr) Compositions et procédés d'administration de médicaments par voie orale
WO2009088414A3 (fr) Formes posologiques pharmaceutiques orales
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
AU2007295179A1 (en) Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
WO2008120207A3 (fr) Compositions pour administration nasale
WO2008038003A3 (fr) Compositions pharmaceutiques
WO2009085990A3 (fr) Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci
SI2046298T1 (sl) Farmacevtska odmerna oblika, ki vsebuje farmacevtsko sprejemljiv solubilizirni sestavek
IL181382A0 (en) Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
WO2007086078A3 (fr) Compositions pharmaceutiques atypiques et processus de preparation correspondant
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
WO2010097243A3 (fr) Procédé de fabrication de formes posologiques orales de solifénacine et de ses sels pharmaceutiquement acceptables
WO2012010669A3 (fr) Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique
WO2009140341A3 (fr) Compositions d'atorvastatine
PT2231189T (pt) Sistema de distribuição de fármaco para administração de substâncias farmaceuticamente ativas pouco solúveis em água
EP2168586A4 (fr) Ingrédient actif de médicament, médicament, composition pharmaceutique et méthode de traitement de malades souffrant d'un syndrome de démence
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
WO2008060546A3 (fr) Formulations orales
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
WO2008004100A3 (fr) Composés thérapeutiques
WO2007110765A3 (fr) Procedes de preparation d'octreotide
WO2010137040A3 (fr) Nouvelles compositions pharmaceutiques de ranolazine
WO2010109180A8 (fr) Composition pour l'administration de médicaments polymères
WO2009060064A3 (fr) Formulations pharmaceutiques pour l'administration par voie orale de ppi
WO2008039894A3 (fr) Compositions pharmaceutiques d'atorvastatine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10795591

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2784120

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010795591

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012544835

Country of ref document: JP

Ref document number: 2010339907

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010339907

Country of ref document: AU

Date of ref document: 20101216

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1728/KOLNP/2012

Country of ref document: IN